Catalyst Pharma HR chief exits equity in acquisition
CATALYST PHARMACEUTICALS, INC.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CATALYST PHARMACEUTICALS, INC. Chief HR Officer Gregg Russo disposed of equity in connection with the acquisition by Angelini Pharma S.p.A. at $31.50 per share. The report shows the return of 476 common shares plus multiple RSUs and stock options to the issuer for cash consideration. After these transactions, no holdings in the reported securities remain.
Insider Trade Summary
Disposition: 72,262 shares
Disposition
7 txns
Insider
Russo Gregg
Role
Chief HR Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 15,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 6,957 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,349 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,531 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F5 | 2,752 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F5 | 6,197 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 476 | $31.50 | $15K |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (5)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 476 shares
Merger cash price: $31.50 per share
RSUs canceled (lot 1): 6197 RSUs
+4 more
7 metrics
Common shares disposed
476 shares
Common stock returned to issuer at $31.50 per share on 2026-07-15 in connection with the acquisition
Merger cash price
$31.50 per share
Cash consideration per share used to value common stock, RSUs, and options in the Angelini Pharma acquisition
RSUs canceled (lot 1)
6197 RSUs
Restricted Stock Units canceled and converted into cash based on $31.50 per underlying share, vesting in full at merger consummation
RSUs canceled (lot 2)
2752 RSUs
Additional Restricted Stock Units canceled and cashed out at $31.50 per underlying share upon consummation of the acquisition
Options canceled (22.77 strike)
20531 options at $22.77
Stock options canceled and converted into cash equal to ($31.50 - $22.77) per share times 20531 option shares
Options canceled (23.26 strike)
20349 options at $23.26
Stock options canceled and converted into cash equal to ($31.50 - $23.26) per share times 20349 option shares
Post-transaction holdings
0 shares
Total shares and derivative securities reported as held after all dispositions on 2026-07-15
Key Terms
Restricted Stock Units, Disposition to issuer, consummation of the acquisition, Angelini Pharma S.p.A., +1 more
5 terms
Restricted Stock Units financial
"Each reported restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Disposition to issuer financial
"Transaction code D is described as a disposition to issuer of the reported securities"
consummation of the acquisition regulatory
"Securities were disposed of in connection with the consummation of the acquisition by Angelini Pharma"
Angelini Pharma S.p.A. financial
"The reported securities were disposed of in connection with the acquisition by Angelini Pharma S.p.A."
exercise price financial
"Cash payment equals the excess of $31.50 per share over the per-share exercise price of each option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Catalyst Pharmaceuticals (CPRX) report for Gregg Russo?
Gregg Russo reported disposing of 476 common shares, restricted stock units, and stock options to the issuer for cash tied to a $31.50 per share acquisition price, leaving no reported holdings in those specific securities after the Form 4 transactions.
What happened to Gregg Russo’s restricted stock units in the CPRX acquisition?
Each reported restricted stock unit vested in full at the merger’s consummation, was cancelled, and converted into a right to receive cash equal to $31.50 multiplied by the number of shares underlying each RSU, less applicable tax withholdings and authorized deductions.
How were Gregg Russo’s stock options on Catalyst Pharmaceuticals (CPRX) treated?
Each reported stock option was cancelled at the acquisition closing and converted into a cash right equal to ($31.50 minus the option’s exercise price) times the number of option shares, without interest and subject to tax withholdings and other authorized deductions, per the Form 4 footnotes.
Does the Gregg Russo Form 4 for Catalyst Pharmaceuticals (CPRX) indicate a Rule 10b5-1 trading plan?
No. The Rule 10b5-1 checkbox is not marked as affirming a plan, and the footnotes describe transactions occurring in connection with the consummation of the acquisition, not pursuant to a pre-arranged Rule 10b5-1 trading arrangement.
What are Gregg Russo’s reported holdings in CPRX securities after these transactions?
For each reported line item—common stock, restricted stock units, and stock options—the Form 4 shows 0.0000 securities held following the dispositions, indicating that no positions remain in the specific Catalyst Pharmaceuticals instruments covered by this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
